Kingdon Capital Management L.L.C. Purchases New Shares in Oscar Health, Inc. (NYSE:OSCR)

Kingdon Capital Management L.L.C. purchased a new position in shares of Oscar Health, Inc. (NYSE:OSCR) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 900,000 shares of the company’s stock, valued at approximately $5,886,000. Kingdon Capital Management L.L.C. owned 0.42% of Oscar Health at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of OSCR. Envestnet Asset Management Inc. boosted its stake in shares of Oscar Health by 20.1% during the fourth quarter. Envestnet Asset Management Inc. now owns 113,285 shares of the company’s stock worth $279,000 after buying an additional 18,939 shares during the period. Verdad Advisers LP acquired a new stake in Oscar Health during the 4th quarter worth approximately $1,102,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Oscar Health in the 4th quarter valued at approximately $49,000. SG Americas Securities LLC increased its holdings in shares of Oscar Health by 8.5% in the first quarter. SG Americas Securities LLC now owns 45,191 shares of the company’s stock valued at $296,000 after purchasing an additional 3,553 shares during the period. Finally, Southeast Asset Advisors Inc. purchased a new stake in shares of Oscar Health during the first quarter worth approximately $201,000. 66.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OSCR has been the topic of several recent research reports. Morgan Stanley boosted their price objective on shares of Oscar Health from $5.00 to $7.50 and gave the company an “equal weight” rating in a research note on Wednesday, August 30th. Bank of America raised shares of Oscar Health from an “underperform” rating to a “neutral” rating and increased their price target for the stock from $5.40 to $8.75 in a report on Tuesday, June 6th. The Goldman Sachs Group boosted their target price on Oscar Health from $5.50 to $7.50 and gave the stock a “neutral” rating in a research report on Thursday, August 10th. Finally, Credit Suisse Group increased their target price on Oscar Health from $7.00 to $8.50 and gave the stock an “outperform” rating in a research note on Wednesday, August 9th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $6.46.

Insider Buying and Selling at Oscar Health

In other Oscar Health news, Director Sid Sankaran sold 139,635 shares of the firm’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $6.25, for a total transaction of $872,718.75. Following the completion of the transaction, the director now directly owns 295,687 shares in the company, valued at approximately $1,848,043.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Sid Sankaran sold 139,635 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $6.25, for a total value of $872,718.75. Following the completion of the transaction, the director now owns 295,687 shares of the company’s stock, valued at $1,848,043.75. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Victoria Baltrus sold 5,337 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $6.25, for a total transaction of $33,356.25. Following the transaction, the chief accounting officer now directly owns 48,382 shares in the company, valued at approximately $302,387.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,688,286 shares of company stock valued at $53,696,788. Insiders own 25.54% of the company’s stock.

Oscar Health Price Performance

OSCR traded down $0.14 on Friday, hitting $6.45. 1,237,363 shares of the company were exchanged, compared to its average volume of 1,684,749. Oscar Health, Inc. has a fifty-two week low of $2.05 and a fifty-two week high of $9.89. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.21 and a current ratio of 1.21. The firm has a market capitalization of $1.43 billion, a P/E ratio of -2.92 and a beta of 1.07. The business’s fifty day moving average is $7.33 and its 200 day moving average is $6.81.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.26. Oscar Health had a negative return on equity of 49.14% and a negative net margin of 9.55%. The business had revenue of $1.52 billion for the quarter, compared to analyst estimates of $1.38 billion. During the same quarter in the previous year, the company earned ($0.53) EPS. The company’s quarterly revenue was up 49.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Oscar Health, Inc. will post -1.45 EPS for the current year.

Oscar Health Company Profile

Oscar Health, Inc operates as a health insurance in the United States. The company offers Individual and Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payors directly enable their shift to value-based care It also provides reinsurance products.